Xenon Pharmaceuticals Inc (FRA:XP0)
€ 42 -0.4 (-0.94%) Market Cap: 3.12 Bil Enterprise Value: 2.45 Bil PE Ratio: 0 PB Ratio: 3.95 GF Score: 40/100

Q4 2019 Xenon Pharmaceuticals Inc Earnings Call Transcript

Mar 09, 2020 / 08:30PM GMT
Release Date Price: €12.2 (-3.94%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Xenon Pharmaceuticals 2019 Financial Results Earnings Call. (Operator Instructions) As a reminder, today's program is being recorded.

I would now like to introduce your host for today's program, Jodi Regts. Please go ahead.

Jodi Regts
Xenon Pharmaceuticals Inc. - VP of Corporate Affairs & IR

Thank you. Good afternoon. Thanks for joining us on our call and webcast to discuss our 2019 financial and operating results. Joining me on today's call are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer. Following this introduction, Simon will give an overview of Xenon's clinical programs, and then Ian will review our financial results. After that, we will open up the call to your questions.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and results from clinical trials and preclinical development activities,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot